Abstract. Aldosterone (Aldo) accelerates hypertension, proteinuria, and glomerulosclerosis in animal models of malignant hypertension or chronic renal failure. Aldo may exert these deleterious renal effects by elevating renal vascular resistance and glomerular capillary pressure. To test this possibility, directly examined were the action of Aldo on the afferent (Af) and efferent (Ef) arterioles (Arts). Examined were the effect of Aldo added to both the bath and lumen on the intraluminal diameter (measured at the most responsive point) of rabbits. Aldo caused dose-dependent constriction in both arterioles with a higher sensitivity in Ef-Arts. Vasoconstrictor action of Aldo was not affected by a mineralocorticoid receptor antagonist spironolactone and was reproduced by membrane-impermeable albumin-conjugated Aldo, suggesting that the vasoconstrictor actions are nongenomic. Pretreatment with neomycin (a specific inhibitor of phospholipase C) abolished the vasoconstrictor action of Aldo in both arterioles. In addition, the vasoconstrictor action of Aldo on Af-Arts was inhibited by both nifedipine and efonidipine, whereas that on Ef-Arts was inhibited by efonidipine but not nifedipine. The results demonstrate that Aldo causes nongenomic vasoconstriction by activating phospholipase C with a subsequent calcium mobilization thorough L-or T-type voltage-dependent calcium channels in Af-or Ef-Arts, respectively. These vasoconstrictor actions on the glomerular microcirculation may play an important role in the pathophysiology and progression of renal diseases by elevating renal vascular resistance and glomerular capillary pressure.There is increasing evidence that renin-angiotensin-aldosterone system (RAAS) plays an important role in the pathogenesis and progression of renal diseases (1-5). Although angiotensin II (AngII) has been identified as the primary mediator of the system, recent studies have raised the possibility that aldosterone (Aldo), independent of renin-angiotensin, also participates in mediating renal injury (5-10). Greene et al. (7) have evaluated the ability of Aldo to reverse the renal protective effects of RAAS blockade in the 5/6 nephrectomy model of hypertension and glomerulosclerosis. They found that pharmacologic blockade of RAAS with angiotensin-converting enzyme inhibitor and AngII receptor blocker reduces plasma Aldo levels, systolic BP, proteinuria and renal lesions, all of which were reversed when Aldo was infused concurrently. Rocha et al. (8) also demonstrated that renal-protective effects of captopril, an angiotensin-converting enzyme inhibitor, were reversed by an Aldo infusion in stroke-prone spontaneously hypertensive rat (SHRSP), an animal model of malignant hypertension. They found that captopril treatment prevented the development of proteinuria and glomerular-renal vascular lesions with reducing endogenous Aldo levels, whereas subsequent Aldo infusion reversed these protective effects of captopril. Although the underlying mechanisms for these actions are not well defined, Aldo may e...